Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 10;10(8):1940.
doi: 10.3390/biomedicines10081940.

Incident Atrial Fibrillation and In-Hospital Mortality in SARS-CoV-2 Patients

Affiliations

Incident Atrial Fibrillation and In-Hospital Mortality in SARS-CoV-2 Patients

Alessandro Maloberti et al. Biomedicines. .

Abstract

(1) Background: Among the different cardiovascular (CV) manifestations of the coronavirus disease 2019 (COVID-19), arrhythmia and atrial fibrillation (AF) in particular have recently received special attention. The aims of our study were to estimate the incidence of AF in patients hospitalized for COVID-19, and to evaluate its role as a possible predictor of in-hospital all-cause mortality. (2) Methods: We enrolled 3435 people with SARS-CoV2 infection admitted to three hospitals in Northern Italy from February 2020 to May 2021. We collected data on their clinical history, laboratory tests, pharmacological treatment and intensive care unit (ICU) admission. Incident AF and all-cause in-hospital mortality were considered as outcomes. (3) Results: 145 (4.2%) patients developed AF during hospitalization, with a median time since admission of 3 days (I-III quartile: 0, 12). Patients with incident AF were admitted more frequently to the ICU (39.3 vs. 12.4%, p < 0.001), and more frequently died (37.2 vs. 16.9%, p < 0.001). In the Cox regression model, the significant determinants of incident AF were age (HR: 1.041; 95% CI: 1.022, 1.060 per year), a history of AF (HR: 2.720; 95% CI: 1.508, 4.907), lymphocyte count (HR: 0.584; 95% CI: 0.384, 0.888 per 103/µL), estimated glomerular filtration rate (eGFR, HR: 0.988; 95% CI: 0.980, 0.996 per mL/min) and ICU admission (HR: 5.311; 95% CI: 3.397, 8.302). Incident AF was a predictor of all-cause mortality (HR: 1.405; 95% CI: 1.027, 1.992) along with age (HR: 1.057; 95% CI: 1.047, 1.067), male gender (HR: 1.315; 95% CI: 1.064; 1.626), dementia (HR: 1.373; 95% CI: 1.045, 1.803), lower platelet (HR: 0.997; 95% CI: 0.996, 0.998 per 103/µL) and lymphocyte counts (HR: 0.843; 95% CI: 0.725, 0.982 per 103/µL), C-Reactive protein values (HR: 1.004; 95% CI: 1.003, 1.005 per mg/L), eGFR (HR: 0.990; 95% CI: 0.986, 0.994 per mL/min), and ICU admission (HR: 1.759; 95% CI: 1.292, 2.395). (4) Conclusions: Incident AF is a common complication in COVID-19 patients during hospitalization, and its occurrence strongly predicts in-hospital mortality.

Keywords: SARS-CoV-2; in-hospital mortality; incident atrial fibrillation; intensive care unit.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Crude cumulative incidence curves of the all-cause mortality in patients with and without incident AF. The origin was fixed at the median time of incident AF (3 days since hospital admission), and late entry was used for AF patients at the time of AF occurrence.
Figure 2
Figure 2
Crude cumulative incidence curves of the all-cause mortality in patients without incident AF, divided according to the presence/absence of previous AF history and patients with incident AF. The origin was fixed at the median time of incident AF (3 days since hospital admission), and late entry was used for AF patients at the time of AF occurrence.

References

    1. Sardu C., Gambardella J., Morelli M.B., Wang X., Marfella R., Santulli G. Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J. Clin. Med. 2020;9:1417. doi: 10.3390/jcm9051417. - DOI - PMC - PubMed
    1. Ruzzenenti G., Maloberti A., Giani V., Biolcati M., Leidi F., Monticelli M., Grasso E., Cartella I., Palazzini M., Garatti L., et al. COVID and Cardiovascular Diseases: Direct and Indirect Damages and Future Perspective. High Blood Press. Cardiovasc. Prev. 2021;28:439–445. doi: 10.1007/s40292-021-00464-8. - DOI - PMC - PubMed
    1. Mancusi C., Grassi G., Borghi C., Ferri C., Muiesan M.L., Volpe M., Iaccarino G., SARS-RAS Investigator Group Clinical Characteristics and Outcomes of Patients with COVID-19 Infection: The Results of the SARS-RAS Study of the Italian Society of Hypertension. High Blood Press. Cardiovasc. Prev. 2021;28:5–11. doi: 10.1007/s40292-020-00429-3. - DOI - PMC - PubMed
    1. Lakkireddy D.R., Chung M.K., Gopinathannair R., Patton K.K., Gluckman T.J., Turagam M., Cheung J., Patel P., Sotomonte J., Lampert R., et al. Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association. Circulation. 2020;141:e823–e831. doi: 10.1161/circulationaha.120.047063. - DOI - PMC - PubMed
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus—Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585. - DOI - PMC - PubMed